24/7 Wall St.

AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

A $2 Billion Reason Why AstraZeneca Stock Is Down Today

AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in ...
BioSpace

AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; ...
Fierce Pharma

Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge

The European Commission has revoked the EU marketing authorization for Hansoh Pharma’s lung cancer drug Aumseqa (aumolertinib ...

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
BioPharma Dive

AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but ...
Fierce Pharma

Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS

In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...
PharmExec

Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics

Novartis secured an exclusive worldwide license to Abogen’s Abo2203 and options on additional RNA-platform programs, positioning mRNA-encoded biologic expression as a scalable autoimmune therapeutic ...